Treatment approved in combination with ravulizumab or eculizumab, representing minority demographic still suffering after receiving C5 inhibitor therapy for extravascular haemolysis.
![FDA Approves Alexion’s Voydeya as Add-on Treatment for Adults with Extravascular Hemolysis](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Treatment approved in combination with ravulizumab or eculizumab, representing minority demographic still suffering after receiving C5 inhibitor therapy for extravascular haemolysis.